The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD

心房颤动 - HD 风险调整研究的因素识别

基本信息

  • 批准号:
    8678908
  • 负责人:
  • 金额:
    $ 46.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): More than 575,000 Americans have end-stage renal disease, and more than 350,000 receive life-saving dialysis treatment. Previous research has demonstrated that patients undergoing hemodialysis, especially those who are older, are at particular risk to have atrial fibrillation. Atrial fibrillation is associated with poor outcomes including high mortality (40% per year). Little is known about fixed and potentially modifiable ris factors for atrial fibrillation in older patients receiving hemodialysis; there is also only scant evidence about these patients' outcomes after their first diagnosis with atrial fibrillation. From already collected Medicare insurance claims and medical records of a large dialysis provider, we propose to assemble a unique dataset that will provide unprecedented detail about these patients health and the health care they receive. In addition, we will have historical Medicare claims predating these patients' time of dialysis initiation by at least 2 years. Using this unique database, we will be in the unusual situation to be able to exclude patients who had atrial fibrillation before they started dialysis, and therefore be able to study incident atrial fibrillaton. We are proposing to identify potentially modifiable risk factors for incident atrial fibrillation, ith particular focus on laboratory measurements, vital signs, dialysis treatment- related factors, and dialysis facility practices. We will also launch a comprehensive assessment of the outcomes of patients once they are first diagnosed with atrial fibrillation, in comparison to similar patients who have not developed this arrhythmia. Outcomes of interest will cover all relevant domains: all-cause and cause-specific mortality; morbidity with focus on thromboembolic and hemorrhagic outcomes; patient-reported health-related quality of life outcomes; and health care utilization and cost. These studies will fill gaping holes in the currently available evidence. The perhaps most innovative aim will focus on deriving a prediction algorithm for near-term risk of new atrial fibrillation using the high-dimensional and extremely granular data in our dataset and novel bioinformatic methods. We will then validate the algorithm in a completely different later time period in data from the same provider as well as in another dataset from a different dialysis provider. If our approach proves successful in identifying patients at the highest near-term risk of incident atrial fibrillation, we are then in the position to test intervention studies to reducethe risk of imminent atrial fibrillation and thus avoid longer term sequelae of this arrhythmia in thes vulnerable patients. Findings from the proposed work have the potential to impact and improve the care that patients with end-stage renal disease receive. Our results may improve the quality of care received and, thus, the outcomes of this vulnerable patient population. The aims and scope of work are in full congruence with the mission of the National Institutes of Diabetes and Digestive and Kidney Diseases, and more specifically the Division of Kidney, Urologic, and Hematologic Diseases, which will consider this application for funding.
描述(由申请人提供):超过 575,000 名美国人患有终末期肾病,超过 350,000 人接受挽救生命的透析治疗。先前的研究表明,接受血液透析的患者,尤其是年龄较大的患者,患房颤的风险特别高。心房颤动与不良预后相关,包括高死亡率(每年 40%)。对于接受血液透析的老年患者心房颤动的固定和潜在可改变的 ris 因素知之甚少;关于这些患者首次诊断出房颤后的预后的证据也很少。 从 我们已经收集了一家大型透析提供商的医疗保险索赔和医疗记录,我们建议收集一个独特的数据集,该数据集将提供有关这些患者的健康状况及其所接受的医疗保健的前所未有的详细信息。此外,我们将拥有早于这些患者开始透析时间至少 2 年的历史医疗保险索赔。利用这种独特的 数据库中,我们将在不寻常的情况下能够排除在开始透析之前患有房颤的患者,因此能够研究突发房颤。 我们建议确定房颤事件的潜在可改变风险因素,特别关注实验室测量、生命体征、透析治疗相关因素和透析设施实践。我们还将对首次诊断出患有房颤的患者的结果进行全面评估,并与未出现这种心律失常的类似患者进行比较。感兴趣的结果将涵盖所有相关领域:全因死亡率和特定原因死亡率;发病率,重点关注血栓栓塞和出血结果;患者报告的与健康相关的生活质量结果;以及医疗保健的利用和成本。这些研究将填补当前可用证据中的空白。也许最具创新性的目标将集中在使用我们的数据集中的高维和极其精细的数据以及新颖的生物信息学方法来推导新房颤近期风险的预测算法。然后,我们将在完全不同的后期时间段内使用来自同一提供商的数据以及来自不同透析提供商的另一个数据集来验证该算法。如果我们的方法成功地识别出近期发生心房颤动风险最高的患者,那么我们就可以测试干预研究,以降低即将发生心房颤动的风险,从而避免这些易受影响的患者出现心律失常的长期后遗症。 拟议工作的结果有可能影响和改善终末期肾病患者接受的护理。我们的结果可能会提高所接受的护理质量,从而改善这一弱势患者群体的结果。工作的目标和范围与美国国立糖尿病、消化和肾脏疾病研究所的使命完全一致,更具体地说,与肾脏、泌尿和血液疾病部门的使命完全一致,该部门将考虑这项资助申请。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WOLFGANG CHRISTOPH WINKELMAYER其他文献

WOLFGANG CHRISTOPH WINKELMAYER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WOLFGANG CHRISTOPH WINKELMAYER', 18)}}的其他基金

The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
  • 批准号:
    10542356
  • 财政年份:
    2012
  • 资助金额:
    $ 46.56万
  • 项目类别:
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
心房颤动 - HD 风险调整研究的因素识别
  • 批准号:
    8372215
  • 财政年份:
    2012
  • 资助金额:
    $ 46.56万
  • 项目类别:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
  • 批准号:
    10084289
  • 财政年份:
    2012
  • 资助金额:
    $ 46.56万
  • 项目类别:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
  • 批准号:
    10319987
  • 财政年份:
    2012
  • 资助金额:
    $ 46.56万
  • 项目类别:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
  • 批准号:
    9885396
  • 财政年份:
    2012
  • 资助金额:
    $ 46.56万
  • 项目类别:
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
心房颤动 - HD 风险调整研究的因素识别
  • 批准号:
    8517713
  • 财政年份:
    2012
  • 资助金额:
    $ 46.56万
  • 项目类别:
2012 ASN Update on Patient Centered Outcomes Research in Kidney Disease
2012 年 ASN 肾脏疾病以患者为中心的结果研究更新
  • 批准号:
    8458852
  • 财政年份:
    2012
  • 资助金额:
    $ 46.56万
  • 项目类别:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
治疗 HD 贫血的新型药物的有效性和安全性比较
  • 批准号:
    8238024
  • 财政年份:
    2011
  • 资助金额:
    $ 46.56万
  • 项目类别:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
治疗 HD 贫血的新型药物的有效性和安全性比较
  • 批准号:
    8540416
  • 财政年份:
    2011
  • 资助金额:
    $ 46.56万
  • 项目类别:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
治疗 HD 贫血的新型药物的有效性和安全性比较
  • 批准号:
    9038583
  • 财政年份:
    2011
  • 资助金额:
    $ 46.56万
  • 项目类别:

相似国自然基金

基于年龄和空间的非随机混合对性传播感染影响的建模与研究
  • 批准号:
    12301629
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
  • 批准号:
    82373667
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
  • 批准号:
    82304205
  • 批准年份:
    2023
  • 资助金额:
    20 万元
  • 项目类别:
    青年科学基金项目
年龄结构和空间分布对艾滋病的影响:建模、分析与控制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
随机噪声影响下具有年龄结构的布鲁氏菌病动力学行为与最优控制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
  • 批准号:
    10748606
  • 财政年份:
    2024
  • 资助金额:
    $ 46.56万
  • 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
  • 批准号:
    10749539
  • 财政年份:
    2024
  • 资助金额:
    $ 46.56万
  • 项目类别:
Understanding the Mechanisms and Consequences of Basement Membrane Aging in Vivo
了解体内基底膜老化的机制和后果
  • 批准号:
    10465010
  • 财政年份:
    2023
  • 资助金额:
    $ 46.56万
  • 项目类别:
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
TASIS-花生(皮肤内靶向过敏原特异性免疫疗法)贴剂治疗花生过敏的安全性和耐受性
  • 批准号:
    10551184
  • 财政年份:
    2023
  • 资助金额:
    $ 46.56万
  • 项目类别:
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathies
持续的 eIF5A 抑制是 TDP-43 蛋白病脑代谢功能障碍的核心
  • 批准号:
    10557547
  • 财政年份:
    2023
  • 资助金额:
    $ 46.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了